BCDAW
BioCardia, Inc.
Set alert
- Open
- 0.0062
- Prev close
- 0.0063
- Mkt cap
- 10.12K
- Vol
- 18.71K
- Avg vol
- 0
- EPS
- -3.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0061
- High
- 0.0063
- Forward P/E
- 0.00
- Beta
- 1.36
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -3.20
- Beta
- 1.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 468.00K
- Revenue growth
- -14.10%
- Free cash flow
- -5.30M
- Total cash
- 949.00K
- Total debt
- 1.23M
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biocardia.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BCDAW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 0.00% | 58,644 | 357 | Jun 29, 2024 |
| Bank of America Corporation | 0.00% | 5,735 | 34 | Jun 29, 2024 |